The A -844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V leiden carriers

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 5, 2000, Pages 1387-1391

  Morange, P E ^a   Henry, M ^a   Tregouet D ^b   Granel, B ^a   Aillaud, M F ^a   Alessi, M C ^a   Juhan Vague, I ^a  

^a TIMONE HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Factor V Leiden; Genetic polymorphisms; PAI 1; Venous thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE LOCATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HEREDITY; HETEROZYGOTE; HUMAN; MALE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; RISK FACTOR; THROMBOGENESIS; THROMBOPHILIA; VEIN THROMBOSIS;

EID: 0034105686     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.5.1387     Document Type: Article

References (25)

1. Price TP, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med. 1997;127: 895-903.
2. Gandrille S, Greengard JS, Alhenc-Gelas M, Juhan-Vague I, Abgrall JF, Jude B, Griffin JH, Aiach M. Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein-C deficient patients: the French network on the behalf of INSERM. Blood. 1995;86:219-224.
3. Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood. 1994;84:1031-1035.
4. Zöller B, Berntsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood. 1995;85:3518-3523.
5. Van Boven HH, Reitsma PH, Rosendaal FR, Bayston TA, Chowdbury V, Bauer KA, Scharrer I, Conrad J, Lane DA. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost. 1996;75:417-421.
6. Dawson S, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 1993;268:10739-10745.
7. Gubric N, Stegnar M, Peternel P, Kaider A, Binder BR. A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. Thromb Res. 1996;84:431-443.
8. Henry M, Chomiki N, Scarabin PY, Alessi MC, Peiretti F, Arveiler D, Ferrières J, Evans A, Amouyel P, Poirier O, Cambien F, Juhan-Vague I. Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI-1 activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vasc Biol. 1997;17:851-858.
9. Eriksson P, Killan B, Van't Hooft F, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A. 1995;92:1851-1855.
10. Henry M, Tregouët DA, Alessi MC, Aillaud MF, Visvikis S, Siest G, Tiret L, Juhan-Vague I. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas cohort. Arterioscler Thromb Vasc Biol. 1998;18:84-91.
11. Iacovello L, Burzotta F, Di Castelnuovo A, Zito F, Marchioli R, Kluft C, Donati MB. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb Haemost. 1998; 80:1029-1030.
12. Sartori MT, Wiman B, Vettore S, Dazzi F, Girolami A, Patrassi MP. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis. Thromb Haemost. 1998;80:956-960.
13. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation. 1997;95:59-62.
14. Stegnar M, Uhrin P, Peternel P, Mavri A, Salobir-Pajnic B, Stare J, Binder BR. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost. 1998;79: 975-979.
15. Zöller B, Garcia de Frutos P, Dahlbäck B. A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency. Thromb Haemost. 1998;79:802-807.
16. Junker R, Nabavi DG, Wolff E, Lüdemann P, Novak-Göttl U, Käse M, Baümer R, Berndt Ringelstein E, Assmann G. Plasminogen activator inhibitor-1 4G/4G genotype is associated with cerebral sinus thrombosis in factor V Leiden carriers. Thromb Haemost. 1998;80:706-707.
17. Junker R, Bäumer R, Koch HG, Schettler CH, Weber D, Nowak-Göttl U. Heterozygous FV R506Q mutation in childhood thrombosis: a possible link to the plasminogen activator inhibitor-1 (PAI-1) 4G/4G genotype and elevated lipoprotein (a): preliminary results of a single centre pilot study. Fibrinol Protcol. 1999;13:26-29.
18. Miller SA, Dykes DD, Polesky HF. A simple salting-out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1998; 16:1215.
19. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
20. Trégouët DA, Ducimetière P, Tiret L. Testing association between candidate-gene markers and phenotype in related individuals, by use of estimating equations. Am J Hum Genet. 1997;61:189-199.
21. Tiret L, Amouyel P, Rakotovao R, Cambien F, Ducimetière P. Testing for association between disease and linked marker loci: a log-linear-model analysis. Am J Hum Genet. 1991;48:926-934.
22. Zöller B, Svensson PJ, Dahlbäck B, Hillarp A. The A20210 allele of the prothrombin gene is frequently associated with the factor V Arg 506 to Gln mutation but not with protein S deficiency in thrombophilic families. Blood. 1998;91:2210-2211.
23. Tosetto A, Rodeghiero F, Martinelli I, De Stefano V, Missiaglia E, Chiusolo P, Mannucci PM. Additional genetic risk factors for venous thromboembolism in carriers of the factor V Leiden mutation. Br J Haematol. 1998;103:871-987.
24. Martinelli M, Mannucci PM, De Stefano V, Taioli E, Rossi V, Crosti F, Paciaroni K, Leone G, Faioni EM. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood. 1998;92:2353-2358.
25. Lang IM, Marsh JJ, Olman MA, Moser KM, Loskutoff DJ, Schleef RR. Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation. 1994;89:2715-2721.